PT-141
Janoshik
Batch PT-CA-26A-01
PT-141
Melanocortin Receptor Research Peptide
PT-141 is a synthetic peptide studied in laboratory settings for its interaction with melanocortin receptor pathways involved in neuroendocrine signaling. Research commonly examines its receptor-binding activity, downstream signaling effects, and modulation of central nervous system communication in controlled experimental models.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
PT-141, also known as bremelanotide in scientific literature, is a synthetic peptide analogue derived from melanocortin receptor research. It is developed for controlled laboratory investigation involving melanocortin receptor signaling systems.
In experimental models, PT-141 is studied for its interaction with melanocortin receptors and associated neuroendocrine signaling pathways under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
PT-141 is a synthetic melanocortin receptor agonist evaluated in research focused on melanocortin pathway signaling and neuroendocrine regulatory systems. Experimental studies examine receptor-binding dynamics and downstream signaling frameworks within controlled laboratory environments.
Preclinical and clinical research publications have explored its receptor interaction characteristics and pathway-level signaling mechanisms under structured experimental conditions.
PT-141 originated from investigations into melanocortin receptor agonists derived from α-melanocyte–stimulating hormone (α-MSH) analogues. Research into melanocortin signaling pathways led to the development of synthetic peptides designed to selectively interact with melanocortin receptor subtypes.
Subsequent studies documented its receptor-binding profile and neuroendocrine signaling properties in experimental models.
Laboratory investigations into PT-141 have focused on melanocortin receptor activation models and neuroendocrine signaling pathways. Research frameworks evaluate receptor-mediated interaction, melanocortin pathway dynamics, and regulatory signaling mechanisms under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Melanocortin receptor activation models
Addressed on this page by Diamond 2004. The work appeared in Int J Impot Res. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Diamond, L.E. et al. (2004) — Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16(1):51–59.
Neuroendocrine signaling pathway studies
No paper cited on this page reports on neuroendocrine. This heading marks where PT-141 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
α-MSH analogue research frameworks
No paper cited on this page reports on analogue. This heading marks where PT-141 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Receptor subtype interaction investigations
Addressed on this page by Diamond 2004. The work appeared in Int J Impot Res. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Diamond, L.E. et al. (2004) — Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16(1):51–59.
The references section of this page cites 4 primary papers published between 2004 and 2025 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for PT-141, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
PT-141 is also referred to as bremelanotide, PT141.
Approved prescription medicines containing the same active ingredient are sold under the brand name Vyleesi. The material supplied here is not those products and is not interchangeable with them. Those are regulated pharmaceuticals manufactured to a licensed specification and dispensed under medical supervision. This is a research compound, and what is published for it is its measured purity and content per lot.
PT-141 is commonly described online in connection with increased libido and sexual function. In the research literature the same compound is filed under melanocortin receptor activation models, neuroendocrine signaling pathway studies and α-MSH analogue research frameworks.
Of the 4 papers cited on this page, published between 2004 and 2025, 3 report work in human participants — Kingsberg 2019, Clayton 2016 and Diamond 2004. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for PT-141 is per lot, not per product. The current 10mg lot PT-CA-26A-01 returned 99.864% purity, 11.86 mg measured, 118.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is PT-141; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for PT-141, this lot measured 118.6% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for PT-141. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy PT-141 in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
PT-141 is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 7 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (10mg / Single Vial, 10mg / 5-Pack, 10mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized PT-141. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 134(5):899–908.
PubMedBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 12(3):325–337.
PubMedDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16(1):51–59.
PubMedFemale Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99